nitazoxanide
Selected indexed studies
- Nitazoxanide and COVID-19: A review. (Mol Biol Rep, 2022) [PMID:36094778]
- Nitazoxanide treatment for norovirus infection in solid organ transplant recipients. (Clin Transplant, 2022) [PMID:35032413]
- High-throughput screening unveils nitazoxanide as a potent PRRSV inhibitor by targeting NMRAL1. (Nat Commun, 2024) [PMID:38844461]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nitazoxanide and COVID-19: A review. (2022) pubmed
- Nitazoxanide treatment for norovirus infection in solid organ transplant recipients. (2022) pubmed
- High-throughput screening unveils nitazoxanide as a potent PRRSV inhibitor by targeting NMRAL1. (2024) pubmed
- Nitazoxanide. (2005) pubmed
- Nitazoxanide protects against experimental ulcerative colitis through improving intestinal barrier and inhibiting inflammation. (2024) pubmed
- Nitazoxanide: a first-in-class broad-spectrum antiviral agent. (2014) pubmed
- Nitazoxanide in the Treatment of Intestinal Parasitic Infections in Children: A Systematic Review and Meta-Analysis. (2020) pubmed
- Role of nitazoxanide as a repurposed drug in the treatment and management of various diseases. (2021) pubmed
- Nitazoxanide: Jack of All, Master of None? (2020) pubmed
- Nitazoxanide for chronic hepatitis C. (2014) pubmed